Needham analyst Serge Belanger maintained a Buy rating on KalVista Pharmaceuticals (KALV) today and set a price target of $28.00. The company’s shares closed last Monday at $10.40, close to its 52-week low of $9.86.
According to TipRanks.com, Belanger is a 1-star analyst with an average return of -2.3% and a 32.4% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, Collegium Pharmaceutical, and Zynerba Pharmaceuticals.
KalVista Pharmaceuticals has an analyst consensus of Hold.
See today’s analyst top recommended stocks >>
Based on KalVista Pharmaceuticals’ latest earnings release for the quarter ending October 31, the company reported a quarterly GAAP net loss of $5.9 million. In comparison, last year the company had a GAAP net loss of $3.96 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: hereditary angioedema (HAE) and diabetic macular edema (DME).
